Dr Reddy's Laboratories said in a filing to the BSE that the tablets are in the strengths of 25 mg, 50 mg, 100 mg and 200 mg.
The company's product is a generic version of GSK Group of companies' Lamictal tablets, it added.
"The Lamictal ODT brand and generic had US sales of approximately $65.5 million MAT for the most recent twelve months ending July 2016 according to IMS Health," Dr Reddy's Laboratories said.
Shares in Dr Reddy's ended 0.80 per cent higher at Rs 3,078.65 apiece on the BSE, whose benchmark Sensex index finished up 0.08 per cent.
Get Breaking news, live coverage, and Latest News from India and around the world on NDTV.com. Catch all the Live TV action on NDTV 24x7 and NDTV India. Like us on Facebook or follow us on Twitter and Instagram for latest news and live news updates.